Pearson JT - Search Results

1

In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.

Davis JA, Rock DA, Wienkers LC, Pearson JT. Davis JA, et al. Among authors: pearson jt. Drug Metab Dispos. 2012 Oct;40(10):1927-34. doi: 10.1124/dmd.112.046169. Epub 2012 Jun 29. Drug Metab Dispos. 2012. PMID: 22752008

2

Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates.

Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS, Rock DA. Pearson JT, et al. Chem Res Toxicol. 2007 Dec;20(12):1778-86. doi: 10.1021/tx700207u. Epub 2007 Nov 15. Chem Res Toxicol. 2007. PMID: 18001057

3

Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements.

Foti RS, Dickmann LJ, Davis JA, Greene RJ, Hill JJ, Howard ML, Pearson JT, Rock DA, Tay JC, Wahlstrom JL, Slatter JG. Foti RS, et al. Among authors: pearson jt. Xenobiotica. 2008 Mar;38(3):264-80. doi: 10.1080/00498250701802514. Xenobiotica. 2008. PMID: 18274956

4

The combination of chemical and antibody inhibitors for superior P450 3A inhibition in reaction phenotyping studies.

Rock DA, Foti RS, Pearson JT. Rock DA, et al. Among authors: pearson jt. Drug Metab Dispos. 2008 Dec;36(12):2410-3. doi: 10.1124/dmd.108.023572. Epub 2008 Sep 2. Drug Metab Dispos. 2008. PMID: 18765682

5

In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract.

Foti RS, Pearson JT, Rock DA, Wahlstrom JL, Wienkers LC. Foti RS, et al. Among authors: pearson jt. Drug Metab Dispos. 2009 Sep;37(9):1848-55. doi: 10.1124/dmd.109.028043. Epub 2009 Jun 18. Drug Metab Dispos. 2009. PMID: 19541824

6

In vitro modulation of cytochrome P450 reductase supported indoleamine 2,3-dioxygenase activity by allosteric effectors cytochrome b(5) and methylene blue.

Pearson JT, Siu S, Meininger DP, Wienkers LC, Rock DA. Pearson JT, et al. Biochemistry. 2010 Mar 30;49(12):2647-56. doi: 10.1021/bi100022c. Biochemistry. 2010. PMID: 20178337

7

The effects of type II binding on metabolic stability and binding affinity in cytochrome P450 CYP3A4.

Peng CC, Pearson JT, Rock DA, Joswig-Jones CA, Jones JP. Peng CC, et al. Among authors: pearson jt. Arch Biochem Biophys. 2010 May;497(1-2):68-81. doi: 10.1016/j.abb.2010.03.011. Epub 2010 Mar 25. Arch Biochem Biophys. 2010. PMID: 20346909 Free PMC article.

8

Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.

Foti RS, Rock DA, Pearson JT, Wahlstrom JL, Wienkers LC. Foti RS, et al. Among authors: pearson jt. Drug Metab Dispos. 2011 Jul;39(7):1188-95. doi: 10.1124/dmd.111.038505. Epub 2011 Mar 29. Drug Metab Dispos. 2011. PMID: 21447734

9

Cytochrome p450 architecture and cysteine nucleophile placement impact raloxifene-mediated mechanism-based inactivation.

VandenBrink BM, Davis JA, Pearson JT, Foti RS, Wienkers LC, Rock DA. VandenBrink BM, et al. Among authors: pearson jt. Mol Pharmacol. 2012 Nov;82(5):835-42. doi: 10.1124/mol.112.080739. Epub 2012 Aug 2. Mol Pharmacol. 2012. PMID: 22859722

10

Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors.

Foti RS, Pearson JT, Wong SL, Zalikowski JA, Boudreaux MD, Prokop SP, Davis JA, Banfield C, Emery MG, Rock DA, Wahlstrom JL, Wienkers LC, Amore BM. Foti RS, et al. Among authors: pearson jt. Drug Metab Dispos. 2012 Dec;40(12):2239-49. doi: 10.1124/dmd.112.047928. Epub 2012 Aug 28. Drug Metab Dispos. 2012. PMID: 22930276

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

199 results

Search Page

Filters